Research brief · 2026-09-09
What Does MK-677 Actually Do? What the Research Shows
MK-677, known generically as ibutamoren, is different from most compounds in the peptide world in one basic way: it is not a peptide. It is a small synthetic molecule developed by Merck to mimic ghrelin, the body's hunger hormone, at the growth hormone secretagogue receptor. Because it is not a peptide, it survives digestion and was studied as a pill. It has never been approved as a medicine anywhere.
It has been tested in more human trials, across more conditions, than almost any compound sold as a research peptide: healthy older adults, Alzheimer's disease, fibromyalgia, kidney disease and hip fracture recovery. The findings are genuinely mixed.
The clearest data come from a two-year, placebo-controlled trial in 65 healthy older adults by Nass and colleagues, published in the Annals of Internal Medicine in 2008. Daily treatment raised growth hormone and IGF-1 into the range seen in young adults and increased fat-free mass compared with placebo. But the same trial found no improvement in muscle strength or physical function. It also raised fasting blood sugar, reduced insulin sensitivity and raised cortisol. Increased appetite and mild swelling were common. An earlier dose-ranging study by Chapman and colleagues in 1996 found the same hormone pattern and the same blood-sugar rise within weeks.
The disease trials are a different story. A 512-patient Phase 2 Alzheimer's trial sponsored by Merck completed in 2006 and never posted or published results. A 64-patient fibromyalgia trial completed in 2008 with the same silence. An 83-patient hip fracture trial was terminated early.
The limit is who was studied. No trial has tested MK-677 in healthy adults in their twenties to forties, the group it is most marketed to, so whether the metabolic trade-offs seen in older adults are better or worse in younger people is unknown. Long-term cancer risk, given growth hormone's role in cell growth, has not been studied. MK-677 is not approved for human use.
Sources
- Nass R et al., Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults, 2-year RCT, n=65
- Annals of Internal Medicine 2008
- Chapman IM et al., Stimulation of the GH-IGF-I axis by daily oral MK-677 in healthy elderly subjects, dose-ranging RCT, n=32
- Journal of Clinical Endocrinology & Metabolism 1996
- ClinicalTrials.gov NCT00074529, MK-0677 in Alzheimer's disease, Merck, n=512, completed 2006, no results posted
- ClinicalTrials.gov 2006
Peptide Proof reports what studies found. We do not give medical advice, dosing guidance, or treatment recommendations.